Fig 5. Effect of KIR genotype matching on the survival outcomes.
Estimates of cGVHD & relapse free survival (cGRFS, left panel), relapse-free survival (RFS, middle panel) and overall survival (OS, right panel) are presented across discovery [A], validation [B] and combined [C] cohorts. A multivariate Cox Proportional Hazards Regression at the end of follow-up revealed a significantly poorer (p-values <0.05) cGRFS in both discovery and validation cohorts in addition to a combined cohort (discovery + validation) when KIR genotype mismatched donors were used.